Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorSullivan, Frank M.
dc.contributor.authorMair, Frances S.
dc.contributor.authorAnderson, William
dc.contributor.authorArmory, Pauline
dc.contributor.authorBriggs, Andrew
dc.contributor.authorChew, Cindy
dc.contributor.authorDorward, Alistair
dc.contributor.authorHaughney, John
dc.contributor.authorHogarth, Fiona
dc.contributor.authorKendrick, Denise
dc.contributor.authorLittleford, Roberta
dc.contributor.authorMcconnachie, Alex
dc.contributor.authorMcCowan, Colin
dc.contributor.authorMcmeekin, Nicola
dc.contributor.authorPatel, Manish
dc.contributor.authorRauchhaus, Petra
dc.contributor.authorRitchie, Lewis
dc.contributor.authorRobertson, Chris
dc.contributor.authorRobertson, John
dc.contributor.authorRobles-Zurita, Jose
dc.contributor.authorSarvesvaran, Joseph
dc.contributor.authorSewell, Herbert
dc.contributor.authorSproule, Michael
dc.contributor.authorTaylor, Thomas
dc.contributor.authorTello, Agnes
dc.contributor.authorTreweek, Shaun
dc.contributor.authorVedhara, Kavita
dc.contributor.authorSchembri, Stuart
dc.date.accessioned2021-07-29T23:36:40Z
dc.date.available2021-07-29T23:36:40Z
dc.date.issued2021-01-01
dc.identifier.citationSullivan , F M , Mair , F S , Anderson , W , Armory , P , Briggs , A , Chew , C , Dorward , A , Haughney , J , Hogarth , F , Kendrick , D , Littleford , R , Mcconnachie , A , McCowan , C , Mcmeekin , N , Patel , M , Rauchhaus , P , Ritchie , L , Robertson , C , Robertson , J , Robles-Zurita , J , Sarvesvaran , J , Sewell , H , Sproule , M , Taylor , T , Tello , A , Treweek , S , Vedhara , K & Schembri , S 2021 , ' Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging ' , European Respiratory Journal , vol. 57 , no. 1 , 2000670 . https://doi.org/10.1183/13993003.00670-2020en
dc.identifier.issn0903-1936
dc.identifier.otherPURE: 269472207
dc.identifier.otherPURE UUID: 82a18aa2-f4d4-49e0-b0cc-0674e82071f7
dc.identifier.othercrossref: 10.1183/13993003.00670-2020
dc.identifier.otherPubMed: 32732334
dc.identifier.otherORCID: /0000-0002-9466-833X/work/78528372
dc.identifier.otherScopus: 85092169225
dc.identifier.otherWOS: 000625355700008
dc.identifier.urihttp://hdl.handle.net/10023/23682
dc.descriptionFunding: Scottish Government Health and Social Care Directorate, and Oncimmune Ltd.en
dc.description.abstractThe EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. Here we report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent CT scanning to identify those at high risk of lung cancer reduces the incidence of patients with stage III/IV/Unspecified lung cancer at diagnosis, compared with the standard clinical practice at the time the study began. ECLS was a randomised controlled trial of 12 208 participants at risk of developing lung cancer in Scotland. The intervention arm received the EarlyCDT-Lung test and, if test positive, low-dose CT scanning six-monthly for up to 2 years. EarlyCDT-Lung test negative and control arm participants received standard clinical care. Outcomes were assessed at 2 years post-randomisation using validated data on cancer occurrence, cancer staging, mortality and comorbidities. At 2 years, 127 lung cancers were detected in the study population (1.0%). In the intervention arm, 33/56 (58.9%) lung cancers were diagnosed at stage III/IV compared to 52/71 (73.2%) in the control arm. The hazard ratio for stage III/IV presentation was 0.64 (95% confidence interval 0.41, 0.99). There were non-significant differences in lung cancer and all-cause mortality after 2 years. ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic presentation), and was not designed to assess the incremental contribution of the EarlyCDT-Lung test. The observation of a stage-shift towards earlier-stage lung cancer diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds anything to the emerging standard of LDCT.
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofEuropean Respiratory Journalen
dc.rightsCopyright © 2020 ERS. This work has been made available online in accordance with publisher policies or with permission. Permission for further reuse of this content should be sought from the publisher or the rights holder. This is the author created accepted manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at https://doi.org/10.1183/13993003.00670-2020en
dc.subjectLung canceren
dc.subjectDiagnosisen
dc.subjectAutoantibodiesen
dc.subjectScreeningen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectNDASen
dc.subjectBDCen
dc.subjectR2Cen
dc.subject~DC~en
dc.subject.lccRC0254en
dc.titleEarlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imagingen
dc.typeJournal articleen
dc.description.versionPostprinten
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.contributor.institutionUniversity of St Andrews.Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews.Population and Behavioural Science Divisionen
dc.identifier.doihttps://doi.org/10.1183/13993003.00670-2020
dc.description.statusPeer revieweden
dc.date.embargoedUntil2021-07-30


This item appears in the following Collection(s)

Show simple item record